Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 31;20(1):2425535.
doi: 10.1080/21645515.2024.2425535. Epub 2024 Nov 18.

Systematic literature review on the clinical and economic burden of human papillomavirus-related diseases in select areas in the Asia-Pacific region

Pei-Jen Lou  1 , Wanatpreeya Phongsamart  2 , Isaya Sukarom  3 , Ying-Hui Wu  4 , Omer Zaidi  5 , Frieda Du  6 , Alyssa Simon  5 , Mark Bernauer  5
Affiliations

Systematic literature review on the clinical and economic burden of human papillomavirus-related diseases in select areas in the Asia-Pacific region

Pei-Jen Lou et al. Hum Vaccin Immunother. .

Abstract

Compared with Europe and America, adoption of human papillomavirus (HPV) vaccination into national immunization programs across the Asia-Pacific (AP) region has remained low. Moreover, HPV burden in this region has not been reviewed comprehensively. Therefore, this systematic literature review (SLR) aimed to summarize the clinical and economic burden of HPV and HPV-related diseases in select AP areas. An SLR was conducted January 2000-February 2022 using MEDLINE/Embase. Observational studies reporting incidence, prevalence, costs, or healthcare resource utilization (HCRU) of HPV and HPV-related disease among adults (≥18 years) from select AP areas were included. A total of 254 publications were included. Reported incidence per 100,000 person-years was 15.4-252.0 for cervical cancer (n = 5 publications), 0.2-55.5 for head and neck cancer (n = 7 publications), and 0.2-13.7 for anal cancer (n = 4 publications). Prevalence rates were 9.1%-100% for cervical cancer (n = 40 publications), 0.0%-95.6% for head and neck cancer (n = 48 publications), 0.0%-100% for anal cancer (n = 4 publications), 36.0%-79.6% for penile cancer (n = 4 publications), and 44.0%-82.0% for vaginal/vulvar cancer (n = 3 publications). Few studies reported on costs or HCRU, and high data variability was observed. Despite data variability, the high burden of HPV and HPV-related diseases makes clear the need for effective HPV screening, greater education, and reductions in vaccine hesitancy, particularly among lower- and middle-income areas. Improved data collection measures should be considered in data-scarce areas to better inform policy decision-making and improve monitoring of the impact of HPV vaccination.

Keywords: Asia Pacific; cost; genotype; healthcare resource utilization; human papillomavirus; incidence; prevalence.

PubMed Disclaimer

Conflict of interest statement

Pei-Jen Lou: Received study funding from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Wanatpreeya Phongsamart: Received study funding from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and from GSK. Isaya Sukarom: Employee of MSD Thailand. Ying-Hui Wu: Employee of MSD Taiwan. Omer Zaidi, Frieda Du, Alyssa Simon, Mark Bernauer: Employees of OPEN Health. The authors declare no other competing interests.

Figures

Figure 1.
Figure 1.
PRISMA diagram.
Figure 2.
Figure 2.
Prevalence of HPV in cervical cancer cases across studies by country.
Figure 3.
Figure 3.
Total costs.
Figure 4.
Figure 4.
Direct costs.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Brianti P, De Flammineis E, Mercuri SR.. Review of HPV-related diseases and cancers. New Microbiol. 2017. Apr;40(2):80–12. - PubMed
    1. Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010. Dec 15;202(12):1789–1799. doi:10.1086/657321. - DOI - PubMed
    1. de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007. Jul;7(7):453–459. doi:10.1016/S1473-3099(07)70158-5. - DOI - PubMed
    1. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007. Aug 1;121(3):621–632. doi:10.1002/ijc.22527. - DOI - PubMed
    1. Anic GM, Lee JH, Stockwell H, Rollison DE, Wu Y, Papenfuss MR, Villa LL, Lazcano-Ponce E, Gage C, Silva RJC, et al. Incidence and human papillomavirus (HPV) type distribution of genital warts in a multinational cohort of men: the HPV in Men Study. J Infect Dis. 2011. Dec 15. 204(12):1886–1892. doi:10.1093/infdis/jir652. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances